<DOC>
	<DOC>NCT03047031</DOC>
	<brief_summary>This is an active surveillance study to monitor the real world safety of nintedanib in Indian patients with Idiopathic Pulmonary Fibrosis. The safety of nintedanib has been assessed in clinical trials. Since only 20 patients from India were enrolled in the INPULSIS trials, the safety data on Indian patients is limited. In this active surveillance, the safety of nintedanib in IPF patients will be examined in Indian real world setting</brief_summary>
	<brief_title>Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Patients with IPF (IPFtreatment na√Øve or pretreated) who are newly prescribed nintedanib according to the package insert. Willing and able to provide the informed consent. Patients in whom further visit/contact is possible during the planned period of active surveillance. Patients who have taken nintedanib before participation in this active surveillance. Patients who are being treated with pirfenidone. Patients who are participating in a clinical trial or other IPF registries.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>